Sheddase inhibitors combined with CD30-binding immunotherapeutics for the treatment of CD30 positive diseases
US7910108B2 · kind B2 · utility
0Cited by
78References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 4, 2007 |
| Grant date | Mar 22, 2011 |
| Priority date | — |
| Expiry date | Jun 4, 2027 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/505
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is directed to pharmaceutical methods for the treatment of CD30 positive diseases, such as Hodgkin's disease, by administration of a combination of at least one sheddase inhibitor and at least one anti-CD30 immunotherapeutic.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.